Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Serial biopsies/fine-needle aspirates and their assessment.

Boeddinghaus I, Johnson SR.

Methods Mol Med. 2006;120:29-41.

PMID:
16491590
2.

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A'Hern R.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1024s-1030s.

3.

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group.

J Clin Oncol. 2005 Aug 1;23(22):5108-16. Epub 2005 Jul 5.

PMID:
15998903
4.

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE.

J Clin Oncol. 2005 Apr 10;23(11):2477-92. Epub 2005 Mar 14.

PMID:
15767642
5.

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G; IMPACT Trialists.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s.

6.

Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors.

Boeddinghaus IM, Dowsett M.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):85-91. Review.

PMID:
11850211
7.

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I.

Cancer Res. 2001 Dec 1;61(23):8452-8.

8.

Clinical studies of apoptosis and proliferation in breast cancer.

Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE.

Endocr Relat Cancer. 1999 Mar;6(1):25-8. Review.

PMID:
10732783
9.

Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.

Cancer Res. 1999 Aug 1;59(15):3646-51.

Supplemental Content

Loading ...
Support Center